Codexis, Inc. (CDXS)

Market Cap	429.68M
Revenue (ttm)	64.45M
Net Income (ttm)	-62.09M
Shares Out	81.38M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,664,627
Open	5.07
Previous Close	5.12
Day's Range	5.07 - 5.48
52-Week Range	2.53 - 6.08
Beta	2.16
Analysts	Buy
Price Target	11.00 (+108.33%)
Earnings Date	Oct 31, 2024

About CDXS

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company’s platform is also used f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXS
• Website: https://www.codexis.com

Financial Performance

In 2023, Codexis's revenue was $70.14 million, a decrease of -49.39% compared to the previous year's $138.59 million. Losses were -$76.24 million, 127.0% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 108.33% from the latest price.

Price Target

$11.0

(108.33% upside)

Analyst Consensus: Buy